{
    "nct_id": "NCT06731413",
    "official_title": "Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) (either squamous or non- squamous)\n* Stage IV disease OR have recurrent disease and not be candidates for curative treatment such as combined chemo-radiation\n* No previous line of treatment in the recurrent or metastatic setting. Neoadjuvant or adjuvant treatment more than 6 months before enrollment is acceptable.\n* Age 70 or meeting frailty definition or above at the date of signing informed consent\n* Absence of driver mutations that have first line Food and Drug Administration (FDA) approved targeted therapy\n* PD-L1 tumor proportion score (TPS) of less than 50%\n* Eastern Cooperative Oncology Group (ECOG) PS of 0-3\n* Have measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment\n* Absolute neutrophil count (ANC) ≥ 1,000/μL\n* Platelets ≥ 75,000/μL\n* Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion permitted)\n* Total bilirubin ≤ 2 x institutional upper limit of normal (ULN)\n* Aspartate amino transferase (AST)serum glutamic-oxaloacetic transaminase (SGOT) /alanine aminotransferase (ALT)serum glutamic-pyruvic transaminase (SGPT) ≤ 5.0 × institutional ULN\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with life expectancy of less than 3 months at the time of enrollment\n* Has active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, or immunosuppressive drugs)\n* Diagnosis of interstitial lung disease\n* Creatinine clearance of <30 mL/min\n* Symptomatic, untreated central nervous system (CNS) disease or leptomeningeal disease. Patients with asymptomatic or treated CNS disease are eligible\n* Required ongoing use of immunosuppressive medication, including steroids, with the following allowable exceptions:\n\n  * Doses less than or equal to the equivalent of prednisone 10 mg daily\n  * Short courses of steroids that are discontinued prior to enrollment\n  * Inhaled, intranasal and/or topical steroids\n  * Dexamethasone taper for treating vasogenic edema associated with CNS disease",
    "miscellaneous_criteria": ""
}